Ovid Therapeutics Company Insiders
OVID Stock | USD 0.43 0.05 10.42% |
Ovid Therapeutics employs about 23 people. The company is managed by 18 executives with a total tenure of roughly 9 years, averaging almost 0.0 years of service per executive, having 1.28 employees per reported executive. Evaluation of Ovid Therapeutics' management performance can provide insight into the firm performance.
Dirk Haasner President Senior Vice President - Global Regulatory Affairs |
Ovid |
Ovid Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.309) % which means that it has lost $0.309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3388) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.8. At present, Ovid Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 235.2 K, whereas Other Assets are forecasted to decline to 1.09.As of March 21, 2025, Common Stock Shares Outstanding is expected to decline to about 47.1 M. The current year's Net Loss is expected to grow to about (59.2 M)
Ovid Therapeutics Workforce Comparison
Ovid Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 822. Ovid Therapeutics holds roughly 23.0 in number of employees claiming about 2.8% of equities under Health Care industry.
Ovid Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ovid Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ovid Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ovid Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jeffrey Rona six days ago Acquisition by Jeffrey Rona of 43750 shares of Ovid Therapeutics subject to Rule 16b-3 | ||
Jeffrey Rona over a week ago Acquisition by Jeffrey Rona of 43750 shares of Ovid Therapeutics subject to Rule 16b-3 | ||
Papadopoulos Stelios over two weeks ago Insider Trading | ||
Papadopoulos Stelios over two weeks ago Insider Trading | ||
Jeffrey Rona over three weeks ago Disposition of 02 shares by Jeffrey Rona of Ovid Therapeutics at 0.56 subject to Rule 16b-3 | ||
Alexander Margaret A. over three weeks ago Acquisition by Alexander Margaret A. of 43750 shares of Ovid Therapeutics subject to Rule 16b-3 | ||
Alexander Margaret A. over a month ago Acquisition by Alexander Margaret A. of 6810 shares of Ovid Therapeutics at 0.73 subject to Rule 16b-3 | ||
Jeffrey Rona over two months ago Acquisition by Jeffrey Rona of 175000 shares of Ovid Therapeutics at 2.82 subject to Rule 16b-3 |
Ovid Therapeutics Notable Stakeholders
An Ovid Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ovid Therapeutics often face trade-offs trying to please all of them. Ovid Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ovid Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dirk Haasner | Senior Vice President - Global Regulatory Affairs | Profile | |
Meg Alexander | Chief Officer | Profile | |
Claude MD | Head RD | Profile | |
SPHR SHRMSCP | VP Facilities | Profile | |
Jason MBA | Chief Officer | Profile | |
Lora Pike | Senior Relations | Profile | |
Garret Bonney | Investor Officer | Profile | |
MBA JD | General Counsel | Profile | |
Simon Kelner | Chief Officer | Profile | |
Zoology Dphil | CEO Pres | Profile | |
Julia Tsai | Senior Development | Profile | |
Tom Parry | Vice Development | Profile | |
Toshiya DVM | Head Research | Profile | |
Zhong Zhong | Chief Officer | Profile | |
Manoj MD | Chief Officer | Profile | |
DSc FACP | Founder Board | Profile | |
Jeffrey Rona | Principal Officer | Profile | |
MPH MD | Senior Affairs | Profile |
About Ovid Therapeutics Management Performance
The success or failure of an entity such as Ovid Therapeutics often depends on how effective the management is. Ovid Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ovid management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ovid management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.29) | (0.30) | |
Return On Capital Employed | (0.76) | (0.80) | |
Return On Assets | (0.29) | (0.30) | |
Return On Equity | (0.39) | (0.41) |
Please note, the presentation of Ovid Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ovid Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ovid Therapeutics' management manipulating its earnings.
Ovid Therapeutics Workforce Analysis
Traditionally, organizations such as Ovid Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ovid Therapeutics within its industry.Ovid Therapeutics Manpower Efficiency
Return on Ovid Therapeutics Manpower
Revenue Per Employee | 24.6K | |
Revenue Per Executive | 31.4K | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 1.5M | |
Working Capital Per Employee | 2M | |
Working Capital Per Executive | 2.5M |
Complementary Tools for Ovid Stock analysis
When running Ovid Therapeutics' price analysis, check to measure Ovid Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ovid Therapeutics is operating at the current time. Most of Ovid Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ovid Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ovid Therapeutics' price. Additionally, you may evaluate how the addition of Ovid Therapeutics to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |